15 July 2026

MediciNova announced that the target enrollment of 200 patients has been achieved in the SEANOBI-ALS study (Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers in ALS ; NCT 06743776) evaluating MN‑166 (ibudilast) in patients with amyotrophic lateral sclerosis (ALS).

The Expanded Access Program SEANOBI study is funded by National Institute of Neurological Disorders and Stroke (NINDS) National Institutes of Health (NIH) supported under the ACT for ALS. This program is designed to provide MN‑166 (ibudilast) to individuals living with ALS who are not eligible to participate in ongoing randomized clinical trials. Reaching this enrollment milestone reflects the strong engagement of the ALS community and the dedicated efforts of patients, families, investigators, and clinical staff involved in the program.

Active participants in the SEANOBI-ALS study remain on-track with treatment and protocol-specified follow-ups. Final patient follow-ups are projected to conclude in early 2027, triggering the data analysis phase to support upcoming scientific presentations and peer-reviewed publications by an academic lead investigator.

MN‑166 (ibudilast) is an orally available small‑molecule inhibitor of phosphodiesterase‑4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). The compound is currently being evaluated across multiple neuroinflammatory and neurodegenerative indications, including ALS. MediciNova announced in September 2025 that it successfully completed enrollment of the target number of participants in its COMBAT-ALS Phase 2b/3 clinical trial of MN-166.

Dr. Yuichi Iwaki, President and CEO of MediciNova, commented: “Achieving full enrollment of 200 patients in this NIH‑funded SEANOBI-ALS study marks an extraordinary milestone for the ALS community. We are deeply grateful to the patients and families who have chosen to participate, as well as to the NIH for its vital support through the ACT for ALS. Their partnership has successfully enabled access to the investigational drug MN‑166 (ibudilast) for individuals who otherwise lacked clinical trial options, and we remain entirely focused on executing the remaining protocol steps with the utmost urgency and care.”

Source: MediciNova